Marina E. Emborg

Marina E. Emborg

Auto-generated profile, based on publicly available information

Marina E. Emborg

Wisconsin National Primate Research Center, University of Wisconsin-Madison, United States

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in ILAR Journal
Verified
Journal Article
Open access
PDF file
MEMarina E. Emborg
Marina E. Emborg
Nonhuman primate (NHP) models of Parkinson's disease (PD) play an essential role in the understanding of PD pathophysiology and the assessment of PD therapies. NHP research enabled the identification of environmental risk factors for the development of PD. Electrophysiological studies in NHP models of PD identified the neural circuit responsible for PD motor symptoms, and this knowledge led to the development of subthalamic surgical ablation and deep brain stimulation. Similar to human PD patients, parkinsonian monkeys are responsive to dopamine replacement therapies and present complications associated with their long-term use, a similarity that facilitated the assessment of new symptomatic treatments, such as dopaminergic agonists. New generations of compounds and novel therapies that use directed intracerebral delivery of drugs, cells, and viral vectors benefit from preclinical evaluation in NHP models of PD. There are several NHP models of PD, each with characteristics that make it suitable for the study of different aspects of the disease or potential new therapies. Investigators who use the models and peer scientists who evaluate their use need information about the strengths and limitations of the different PD models and their methods of evaluation. This article provides a critical review of available PD monkey models, their utilization, and how they compare to emerging views of PD as a multietiologic, multisystemic disease. The various models are particularly useful for representing different aspects of PD at selected time points. This conceptualization provides clues for the development of new NHP models and facilitates the clinical translation of findings. As ever, successful application of any model depends on matching the model to the scientific question to be answered. Adequate experimental designs, with multiple outcome measures of clinical relevance and an appropriate number of animals, are essential to minimize the limitations of models and increase their predictive clinical validity.

5 August 2011 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
CSChristine R Swanson
Christine R Swanson
VJValerie Joers
Valerie Joers
VBViktoriya Bondarenko
Viktoriya Bondarenko
KBKevin Brunner
Kevin Brunner
HSHeather A Simmons
Heather A Simmons
MEMarina E Emborg
Marina E Emborg
Background: Activation of the peroxisome proliferator-activated receptor gamma (PPAR-γ) has been proposed as a possible neuroprotective strategy to slow down the progression of early Parkinson's disease (PD). Here we report preclinical data on the use of the PPAR-γ agonist pioglitazone (Actos®; Takeda Pharmaceuticals Ltd.) in a paradigm resembling early PD in nonhuman primates. Methods: Rhesus monkeys that were trained to perform a battery of behavioral tests received a single intracarotid arterial injection of 20 ml of saline containing 3 mg of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Twenty-four hours later the monkeys were assessed using a clinical rating scale, matched accordingly to disability, randomly assigned to one of three groups [placebo (n = 5), 2.5 (n = 6) or 5 (n = 5) mg/kg of pioglitazone] and their treatments started. Three months after daily oral dosing, the animals were necropsied. Results: We observed significant improvements in clinical rating score (P = 0.02) in the animals treated with 5 mg/kg compared to placebo. Behavioral recovery was associated with preservation of nigrostriatal dopaminergic markers, observed as higher tyrosine hydroxylase (TH) putaminal optical density (P = 0.011), higher stereological cell counts of TH-ir (P = 0.02) and vesicular monoamine transporter-2 (VMAT-2)-ir nigral neurons (P = 0.006). Stereological cell counts of Nissl stained nigral neurons confirmed neuroprotection (P = 0.017). Pioglitazone-treated monkeys also showed a dose-dependent modulation of CD68-ir inflammatory cells, that was significantly decreased for 5 mg/kg treated animals compared to placebo (P = 0.018). A separate experiment to assess CSF penetration of pioglitazone revealed that 5 mg/kg p.o. induced consistently higher levels than 2.5 mg/kg and 7.5 mg/kg. p.o. Conclusions: Our results indicate that oral administration of pioglitazone is neuroprotective when administered early after inducing a parkinsonian syndrome in rhesus monkeys and supports the concept that PPAR-γ is a viable target against neurodegeneration.

7 April 2021 in Nature
Verified
Journal Article
Open access
PDF file
TCThe SCGE Consortium
The SCGE Consortium
KSKrishanu Saha
Krishanu Saha
ESErik J. Sontheimer
Erik J. Sontheimer
PBP. J. Brooks
P. J. Brooks
MDMelinda R. Dwinell
Melinda R. Dwinell
JZJiangbing Zhou
Jiangbing Zhou
The move from reading to writing the human genome offers new opportunities to improve human health. The United States National Institutes of Health (NIH) Somatic Cell Genome Editing (SCGE) Consortium aims to accelerate the development of safer and more-effective methods to edit the genomes of disease-relevant somatic cells in patients, even in tissues that are difficult to reach. Here we discuss the consortium’s plans to develop and benchmark approaches to induce and measure genome modifications, and to define downstream functional consequences of genome editing within human cells. Central to this effort is a rigorous and innovative approach that requires validation of the technology through third-party testing in small and large animals. New genome editors, delivery technologies and methods for tracking edited cells in vivo, as well as newly developed animal models and human biological systems, will be assembled—along with validated datasets—into an SCGE Toolkit, which will be disseminated widely to the biomedical research community. We visualize this toolkit—and the knowledge generated by its applications—as a means to accelerate the clinical development of new therapies for a wide range of conditions.

1 March 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YTYunlong Tao
Yunlong Tao
SVScott C. Vermilyea
Scott C. Vermilyea
MZMatthew Zammit
Matthew Zammit
JLJianfeng Lu
Jianfeng Lu
MOMiles Olsen
Miles Olsen
SZSu-Chun Zhang
Su-Chun Zhang

1 October 2004 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
MEMarina E. Emborg
Marina E. Emborg

16 November 1998
Verified
Journal Article
Closed access
MEM E Emborg
M E Emborg
SMS Y Ma
S Y Ma
EME J Mufson
E J Mufson
ALA I Levey
A I Levey
MTM D Taylor
M D Taylor
JKJ H Kordower
J H Kordower